KDR and colorectal carcinoma: Since then, the Food and Drug Administration (FDA) has granted approval to aflibercept (inhibitor of VEGF-A), ramucirumab (fully humanized mAb against VEGFR-2) and regorafenib (inhibitor of VEGFR-2) for the treatment of CRC [16].